Table 2.
Median values of serum iron biomarkers in subjects by incident HCC status The UPMC NAFLD Cohort Study, 2004 – 2018
| Serum iron biomarkers | Incident HCC | Free of HCC | |||
|---|---|---|---|---|---|
|
|
|
||||
| N | Median (5%, 95%) | N | Median (5%, 95%) | P* | |
|
| |||||
| Iron (μg/dl) | 188 | 70.5 (19.0, 171.0) | 15,586 | 69.0 (19.0, 141.0) | 0.897 |
| Transferrin Saturation ( %) | 175 | 19.4 (5.0, 49.0) | 13,697 | 20.0 (5.4, 44.0) | 0.704 |
| TIBC (μg/dl) | 224 | 335.5 (174.0, 503.0) | 16,304 | 348.0 (191.0, 485.0) | 0.180 |
| Ferritin (μg /dl) | 219 | 8.3 (0.8, 98.1) | 16,111 | 10.0 (0.9, 70.0) | 0.445 |
HCC: hepatocellular carcinoma; NAFLD: non-alcoholic fatty liver disease; TIBC: total iron binding capacity.
*
Derived from the Wilcoxon rank sum test.